TerminatedNot Applicable

Study of a Novel Interposition Supraciliary Implant in Patients With Open Angle Glaucoma

Stopped: COVID

France27 participantsStarted 2019-03-15

Plain-language summary

The purpose of this study is to evaluate the safety and effectiveness of a novel interposition supraciliary implant as a stand-alone therapy for lowering intraocular pressure (IOP) in patients with primary open angle glaucoma (POAG) who have failed at least one class of topical medical therapy

Who can participate

Age range50 Years – 99 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of POAG Schafer 3 or 4 * Medicated IOP ≥ 21 Exclusion Criteria: * Inflammatory, congenital, traumatic, neovascular, ICE syndrome, angle closure and Schaffer 1 and 2 glaucoma * Non surgical interventional treatment (cyclophotocoagulation, ultrasounds, …) * Medical treatment having intraocular hypotensive effect

What they're measuring

Assess post-op IOP reduction

Timeframe: 6 months

Assess post-op IOP clinical success

Timeframe: 6 months

Trial details

NCT IDNCT03736655

SponsorCiliatech

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2021-04-01

View on ClinicalTrials.gov More Glaucoma, Open-Angle trials